BioDiem Ltd brings an international focus to finding, adding value to and commercialising world-class research for vaccines and vaccine technologies. The company uses a cost-efficient approach to development through collaborations with academic centres of excellence, contract research organizations and partnerships with international biopharmaceutical companies. It receives income from licences to its LAIV technology.

BioDiem’s leading product is the Live Attenuated Influenza Virus (LAIV) technology, which has been used to develop a novel intranasal vaccine for seasonal and pandemic influenza. The LAIV vaccine can be produced using egg-based and cell-based manufacturing methods.  BioDiem is also investigating the use of its proprietary LAIV technology as a vaccine vector.